Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Zoila Gándara is active.

Publication


Featured researches published by Zoila Gándara.


European Journal of Medicinal Chemistry | 2011

An application of two MIFs-based tools (Volsurf+ and Pentacle) to binary QSAR: the case of a palinurin-related data set of non-ATP competitive glycogen synthase kinase 3β (GSK-3β) inhibitors.

Giuseppe Ermondi; Giulia Caron; Isela Garcia Pintos; Michela Gerbaldo; Manuel Pérez; Daniel I. Perez; Zoila Gándara; Ana Martinez; Generosa Gómez; Yagamare Fall

VolSurf+ and GRIND descriptors extract the information present in MIFs calculated by GRID: the first are simpler to interpret and generally applied to ADME-Tox topics, whereas the latter are more sophisticated and thus more suited for pharmacodynamics events. Here we present a study which compares binary QSAR models obtained with VolSurf+ descriptors and GRIND for a data set of non-ATP competitive GSK-3β inhibitors chemically related to palinurin for which the biological activity is expressed in binary format. Results suggest not only that the simpler Volsurf+ descriptors are good enough to predict and chemically interpret the investigated phenomenon but also a bioactive conformation of palinurin which may guide future design of ATP non-competitive GSK-3 inhibitors.


RSC Advances | 2016

[3,3]-Sigmatropic rearrangement mediated synthesis of chiral building blocks for the preparation of Gemini and its analogs

Gonzalo Pazos; Manuel Pérez; Zoila Gándara; Generosa Gómez; Yagamare Fall

A novel synthetic methodology for the preparation of Gemini vitamin D3 analogs has been developed. Our procedure uses a key sigmatropic rearrangement which allows control over the C-20 stereochemistry, providing a versatile method to introduce novel side-chains to the vitamin D scaffold giving access to new analogs with potentially interesting biological properties.


Current Topics in Medicinal Chemistry | 2014

Gemini Analogs of Vitamin D

Gonzalo Pazos; Marcos L. Rivadulla; Xenxo Pérez-García; Zoila Gándara; Manuel Pérez

The Gemini analogs are the last significant contribution to the family of vitamin D derivatives in medicine, for the treatment of cancer. The first Gemini analog was characterized by two symmetric side chains at C-20. Following numerous modifications, the most active analog bears a C-23-triple bond, C-26, 27- hexafluoro substituents on one side chain and a terminal trideuteromethylhydroxy group on the other side chain. This progression was possible due to improvements in the synthetic methods for the preparation of these derivatives, which allowed for increasing molecular complexity and complete diastereoselective control at C-20 and the substituted sidechains.


Bioorganic & Medicinal Chemistry Letters | 2012

Synthesis and biological evaluation of a new vitamin D2 analogue

Zoila Gándara; Manuel Pérez; Débora Gisele Salomón; María Julia Ferronato; María Eugenia Fermento; Alejandro C. Curino; María M. Facchinetti; Generosa Gómez; Yagamare Fall

A new vitamin D(2) analogue was synthesized using the Julia-Kocienski olefination. It has antiproliferative effects on cell lines from squamous cell carcinomas of colon and head and neck, but is also as hypercalcaemic as calcitriol in vivo.


European Journal of Medicinal Chemistry | 2017

Structure-activity relationship study of vitamin D analogs with oxolane group in their side chain.

Anna Y. Belorusova; Andrea Martínez; Zoila Gándara; Generosa Gómez; Yagamare Fall; Natacha Rochel

Synthetic analogs of 1α,25-dihydroxyvitamin D3 (1,25(OH)2D3) have been developed with the goal of improving the biological profile of the natural hormone for therapeutic applications. Derivatives of 1,25(OH)2D3 with the oxolane moiety branched in the side chain at carbon C20, act as Vitamin D nuclear Receptor (VDR) superagonists being several orders of magnitude more active than the natural ligand. Here, we describe the synthesis and biological evaluation of three diastereoisomers of (1S, 3R)-Dihydroxy-(20S)-[(2″-hydroxy-2″-propyl)-tetrahydrofuryl]-22,23,24,25,26,27-hexanor-1α-hydroxyvitamin D3, with different stereochemistry at positions C2 and C5 of the oxolane ring branched at carbon C22 (1, C2RC5S; 2, C2SC5R; 3, C2SC5S). These compounds act as weak VDR agonist in transcriptional assays with compound 3 being the most active. X-ray crystallographic analysis of the VDR ligand-binding domain accommodating the three compounds indicates that the oxolane group branched at carbon C22 is not constrained as in case of compound with oxolane group branched at C20 leading to the loss of interactions of the triene group and increased flexibility of the C/D-rings and of the side chain.


Tetrahedron Letters | 2004

Vitamin D and click chemistry. Part 1: A stereoselective route to vitamin D analogues with triazole rings in their side chains

Pedro Lois Suárez; Zoila Gándara; Generosa Gómez; Yagamare Fall


Tetrahedron Letters | 2009

A new, enantioselective synthesis of (+)-isolaurepan

Gonzalo Pazos; Manuel Pérez; Zoila Gándara; Generosa Gómez; Yagamare Fall


Tetrahedron Letters | 2011

Total synthesis of (−)-muricatacin

María Elisa Alén González; Zoila Gándara; Berta Covelo; Generosa Gómez; Yagamare Fall


Tetrahedron | 2012

Enantiodivergent synthesis of (+)- and (−)-isolaurepan

Gonzalo Pazos; Manuel Pérez; Zoila Gándara; Generosa Gómez; Yagamare Fall


Tetrahedron Letters | 2008

The furan approach to azacyclic compounds

Isela García; Manuel Pérez; Zoila Gándara; Generosa Gómez; Yagamare Fall

Collaboration


Dive into the Zoila Gándara's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge